Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...
Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in ...
Terns Pharmaceuticals ( ($TERN) ) has shared an announcement. On November 3, 2025, Terns Pharmaceuticals announced that data from the Phase 1 ...
– Breadth of Alto’s pipeline and Precision Psychiatry Platform™ will be highlighted across twelve posters and presentations at the Society of Biological Psychiatry and American Society of Clinical ...
The regional agency asked for the research to be undertaken aas the prospect of local projects have become a hot button issue.
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. We live in an increasing data-rich world, where forward-thinking organizations are harnessing the ...
Please note: This item is from our archives and was published in 2022. It is provided for historical reference. The content may be out of date and links may no longer function. Tom King, CPA, has ...
Pharmaceuticals announced that 23 abstracts, including six oral presentations, showcasing compelling Revuforj and Niktimvo data were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback